Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic fusion to albumin improves the pharmacokinetic properties of factor IX

1 Jan 2009

Abstract excerpt

Haemophilia B is a X-chromosome linked disease characterised by a deficiency of functionally active coagulation Factor IX (FIX). Patients with severe haemophilia B at risk of recurrent bleeding are treated approximately twice a week in a prophylactic setting by application of FIX concentrates. To increase convenience and compliance of the therapy it is desirable to reduce the dosing frequency by improving the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemophilia Treatment and Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19806248
DOI: 10.1160/th09-04-0255

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic fusion to albumin improves the pharmacokinetic properties of factor IXPMID 19806248Read ↗

Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration.Semantic proximity Read ↗

Recombinant Factor IX for Clinical and Research UseSemantic proximity Read ↗

An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice.Semantic proximity Read ↗

The Function of extravascular coagulation factor IX in haemostasisSemantic proximity Read ↗

A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.Semantic proximity Read ↗

Variants of recombinant factor VIIa with increased intrinsic activity.Semantic proximity Read ↗

Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study.Semantic proximity Read ↗

Alternative therapies for the management of inhibitorsSemantic proximity Read ↗

Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity.Semantic proximity Read ↗

Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.Semantic proximity Read ↗

Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.